ImmunoGen Inc. said Wednesday that it has begun Phase I/IIEuropean clinical trials of Oncolysin S to treat small-cell lungcancer.

The Cambridge, Mass., company (NASDAQ:IMGN) last yearbegan a similar study in the United States.

In the initial study, Oncolysin S is being given to relapsedpatients. Once a maximum tolerated dose is established, thecompany plans to treat patients who are in remission followingconventional chemotherapy. Those trials are expected to beginin the second half of this year.

Oncolysin S consists of blocked ricin, the company's proprietaryform of the plant toxin, linked to a monoclonal antibodytargeted at cancer cells.

ImmunoGen shares closed unchanged at $13.

(c) 1997 American Health Consultants. All rights reserved.